News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Renaissance Technologies LLC significantly reduced its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 51.6% in the first quarter, selling 59,400 shares and retaining 55,800 shares valued at approximately $2.69 million. Despite this reduction and a recent earnings per share miss, analyst sentiment …
Piper Sandler analyst Yasmeen Rahimi reiterated a Buy rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) and set a price target of $93.00. This comes despite the company reporting an increased GAAP net loss in its latest quarter and negative corporate insider sentiment with …
Structure Therapeutics' Chief Commercial Officer, John Joseph Berrios, has filed an initial beneficial ownership statement (Form 3), disclosing his insider holdings as of August 6, 2026. This report was generated by Public Technologies using AI and is based on the original content filed by …
Structure Therapeutics Inc. (GPCR) has filed an initial Form 3 for its Chief Commercial Officer, John Joseph Berrios. This filing, accepted by the SEC on August 7, 2026, indicates no reported buy, sell, or derivative transactions, and no beneficial holdings for Berrios as of …
Citizens has lowered its price target for Structure Therapeutics Inc. (NASDAQ:GPCR) to $110 from $113, while maintaining a Market Outperform rating, citing the potential of its small-molecule GLP agonist, aleniglipron. The company's stock has seen a significant 225% return over the past year, with …
Eighteen brokerages have given Structure Therapeutics Inc. (NASDAQ:GPCR) an average rating of "Moderate Buy," with a consensus 12-month price target of $110.55, significantly higher than its current share price of $52.62. Institutional investors own a substantial 91.78% of the company, with several major firms …
Structure Therapeutics announced its Q2 2026 financial results and provided key business updates, including the initiation of Phase 3 clinical trials for aleniglipron for chronic weight management. The company also reported progress on its dual amylin and calcitonin receptor agonist, ACCG-2671, and highlighted the …
Structure Therapeutics Inc. reported a Q2 net income of -106.159 million USD. The brief article, sourced from Reuters, states that the full details are available to TradingView subscribers.
Structure Therapeutics Inc. reported a wider comprehensive and net loss in the 2026 quarter compared to the previous year, with revenue at ($107.41M), net income at ($106.16M), and diluted EPS at ($0.49). Despite the financial losses, the company made significant clinical progress, including positive …
Structure Therapeutics Inc. has released its earnings summary for the quarter that ended on June 30. The full article detailing these results is available through Reuters on TradingView, which provides access to various news sources.
FMR LLC has filed an amended ownership report for Structure Therapeutics Inc. (GPCR), revealing a beneficial ownership of 28,197,369 shares, which constitutes 13.2% of the company's common stock. The filing details FMR LLC's sole voting power over 28,197,321 shares and sole dispositive power over …
Structure Therapeutics' Chief Scientific Officer, Xichen Lin, recently exercised options for 11,817 Ordinary Shares at $0.34 each, converting them into 3,939 American Depositary Shares (ADS). He then sold all these ADS in two separate trades at weighted average prices of $49.2857 and $50.0290, pursuant …
This article provides financial information for Structure Therapeutics Inc. (NASDAQ: GPCR), focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data placeholder from TradingView, indicating that specific value, change, and percentage change for the P/E ratio are pending …
This article analyzes the price dynamics and execution-aware positioning for Structure Therapeutics Inc. (NASDAQ: GPCR). It highlights weak near and mid-term sentiment but maintains a long-term positive outlook, identifying a mid-channel oscillation pattern. The report provides AI-generated trading strategies including position trading, momentum breakout, …
The article focuses on the "Price to sales forward" metric for Structure Therapeutics Inc. (NASDAQ: GPCR). It outlines where this financial data can be found on the TradingView platform under the company's financials section.
This article provides the balance sheet for Structure Therapeutics Inc (GPCR), detailing its financial health through quarterly and annual data. It presents key financial figures such as cash, assets, liabilities, and equity, alongside year-over-year percentage changes. The article also includes a FAQ section addressing …
This article provides a detailed cash flow statement for Structure Therapeutics Inc (GPCR), presenting quarterly and annual financial data. It covers operating, investing, and financing cash flows, along with free cash flow, and includes FAQs explaining these financial metrics and GPCR's performance in each …
Structure Therapeutics Inc. (GPCR) is presented as a promising biopharmaceutical company with a potential 115% upside, according to analyst targets. Despite its current non-profit phase, typical for biotech firms focused on R&D, the company has a robust pipeline with lead candidate GSBR-1290 in Phase …
This article from TradingKey provides a revenue breakdown for Structure Therapeutics Inc (GPCR). It notes that relevant financial data regarding business segments, regional revenue, and profit contribution for the company have not yet been disclosed. The page includes general company information, stock quotes, and …
This article provides a technical analysis of Structure Therapeutics Inc (GPCR), focusing on support, resistance, indicators, and moving averages. It evaluates various technical indicators like MACD, RSI, and KDJ, alongside different moving averages, to offer a technical summary for the stock. The analysis suggests …
This article provides an analysis of Structure Therapeutics Inc (GPCR), focusing on its valuation metrics. It highlights that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company, indicating a lack of comprehensive valuation information. The company's stock …
This article from TradingKey provides an overview of institutional confidence in Structure Therapeutics Inc. (GPCR). It lists several major institutional shareholders, including Fidelity Management & Research Company LLC and Wellington Management Company, LLP, along with their shareholdings and percentage changes. The data indicates significant …
Structure Therapeutics Inc. (GPCR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions. The company's pipeline includes programs targeting obesity and idiopathic pulmonary fibrosis (IPF). Currently, the stock is trading at $49.120, down 1.68% or …
This article announces the filing of Form 4 for Structure Therapeutics Inc ADR on July 24, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in their company's stock. …
FMR LLC, a major shareholder in Structure Therapeutics Inc. (GPCR), reported the indirect sale of 17,452 American Depositary Shares (ADS) at a weighted average price of $50.07 per ADS through its F-Prime funds. These transactions occurred on July 22, 2026, and despite the sales, …
Search by ticker symbol or company name and select a result to open its chart.